

TK13152

Page: 64

## A 4-Week Oral Dose Toxicity Study of TM5509 in Cynomolgus Monkeys

## Appendix 6 Hematology (females)

Sex: Female Week(s) Relative to Start Date

Mid-High TM5509 80 mg/kg/day	PT	PT	PT	PT	PT	APTT	APTT	APTT	APTT	APTT
	(s)	(s)	(s)	(s)	(s)	(s)	(s)	(s)	(s)	(s)
	-1	1	2	3	4	-1	1	2	3	4
RP5F01	9.5	10.1	10.3	10.7	9.9	22.1	23.5	23.5	22.6	22.6
RP5F02	9.7	9.9	10.0	10.4	10.6	26.3	28.3	27.0	27.9	28.6
RP5F03	10.4	10.2	11.5	11.5	11.6	23.1	22.8	24.5	24.4	24.3
RP5F04	9.7	9.9	10.5	10.1	10.4	26.3	27.6	27.8	27.0	27.1
Mean	9.8	10.0	10.6	10.7	10.6	24.5	25.6	25.7	25.5	25.7
S.D.	0.4	0.1	0.7	0.6	0.7	2.2	2.8	2.0	2.4	2.7
N	4	4	4	4	4	4	4	4	4	4

## A 4-Week Oral Dose Toxicity Study of TM5509 in Cynomolgus Monkeys

## Appendix 6 Hematology (females)

Sex: Female Week(s) Relative to Start Date

Mid-High TM5509 80 mg/kg/day	Fib	Fib	Fib	Fib	Fib
	(mg/dL)	(mg/dL)	(mg/dL)	(mg/dL)	(mg/dL)
	-1	1	2	3	4
RP5F01	165.6	178.7	165.3	161.3	207.2
RP5F02	193.8	220.4	196.4	202.4	233.0
RP5F03	162.8	174.0	158.7	137.7	169.6
RP5F04	195.7	222.9	187.2	190.8	207.2
Mean	179.5	199.0	176.9	173.1	204.3
S.D.	17.7	26.2	17.8	29.2	26.1
N	4	4	4	4	4

TK13152

Page: 66

## A 4-Week Oral Dose Toxicity Study of TM5509 in Cynomolgus Monkeys

## Appendix 6 Hematology (females)

Sex: Female Week(s) Relative to Start Date

High TM5509 300 mg/kg/day	RBC	RBC	RBC	RBC	RBC	HGB	HGB	HGB	HGB	HGB
	(10 <sup>6</sup> /μL)	(10 <sup>6</sup> /μL)	(10 <sup>6</sup> /μL)	(10 <sup>6</sup> /μL)	(10 <sup>6</sup> /μL)	(g/dL)	(g/dL)	(g/dL)	(g/dL)	(g/dL)
	-1	1	2	3	4	-1	1	2	3	4
RP6F01	5.55	5.30	5.49	.	.	13.2	12.6	12.9	.	.
RP6F02	6.12	5.86	5.53	5.22	5.56	14.7	14.1	13.3	12.5	13.4
RP6F03	6.69	6.47	5.75	4.47 E <sup>1</sup>	.	14.1	13.6	11.9	9.5 E <sup>1</sup>	.
RP6F04	6.65	6.21	6.13	5.09 E <sup>1</sup>	.	14.3	13.4	13.2	10.9 E <sup>1</sup>	.
Mean	6.25	5.96	5.73	5.22	5.56	14.1	13.4	12.8	12.5	13.4
S.D.	0.54	0.51	0.29	.	.	0.6	0.6	0.6	.	.
N	4	4	4	1	1	4	4	4	1	1

1 [E, Exclude]

## A 4-Week Oral Dose Toxicity Study of TM5509 in Cynomolgus Monkeys

## Appendix 6 Hematology (females)

Sex: Female Week(s) Relative to Start Date

High TM5509 300 mg/kg/day	HCT					MCV				
	HCT	HCT	HCT	HCT	HCT	MCV	MCV	MCV	MCV	MCV
	(%)	(%)	(%)	(%)	(%)	(fL)	(fL)	(fL)	(fL)	(fL)
	-1	1	2	3	4	-1	1	2	3	4
RP6F01	43.1	40.0	41.7	.	.	77.7	75.4	76.1	.	.
RP6F02	48.4	44.6	40.9	38.9	42.5	79.2	76.1	73.9	74.5	76.5
RP6F03	45.8	45.0	36.7	28.6 E <sup>1</sup>	.	68.4	69.6	63.8	64.1 E <sup>1</sup>	.
RP6F04	47.9	43.4	41.5	33.2 E <sup>1</sup>	.	72.1	69.9	67.7	65.3 E <sup>1</sup>	.
Mean	46.3	43.3	40.2	38.9	42.5	74.4	72.8	70.4	74.5	76.5
S.D.	2.4	2.3	2.4	.	.	5.0	3.5	5.6	.	.
N	4	4	4	1	1	4	4	4	1	1

1 [E, Exclude]

TK13152

Page: 68

## A 4-Week Oral Dose Toxicity Study of TM5509 in Cynomolgus Monkeys

## Appendix 6 Hematology (females)

Sex: Female Week(s) Relative to Start Date

High TM5509 300 mg/kg/day	MCH	MCH	MCH	MCH	MCH	MCHC	MCHC	MCHC	MCHC	MCHC
	(pg)	(pg)	(pg)	(pg)	(pg)	(g/dL)	(g/dL)	(g/dL)	(g/dL)	(g/dL)
	-1	1	2	3	4	-1	1	2	3	4
RP6F01	23.7	23.7	23.5	.	.	30.6	31.5	30.8	.	.
RP6F02	24.0	24.1	24.1	24.0	24.1	30.4	31.7	32.6	32.2	31.5
RP6F03	21.1	21.1	20.7	21.3 E <sup>1</sup>	.	30.8	30.3	32.4	33.3 E <sup>1</sup>	.
RP6F04	21.5	21.5	21.5	21.5 E <sup>1</sup>	.	29.8	30.8	31.7	32.9 E <sup>1</sup>	.
Mean	22.6	22.6	22.5	24.0	24.1	30.4	31.1	31.9	32.2	31.5
S.D.	1.5	1.5	1.6	.	.	0.4	0.6	0.8	.	.
N	4	4	4	1	1	4	4	4	1	1

1 [E, Exclude]

## A 4-Week Oral Dose Toxicity Study of TM5509 in Cynomolgus Monkeys

## Appendix 6 Hematology (females)

Sex: Female Week(s) Relative to Start Date

High TM5509 300 mg/kg/day	%Retic	%Retic	%Retic	%Retic	%Retic	#Retic	#Retic	#Retic	#Retic	#Retic
	(%)	(%)	(%)	(%)	(%)	(10 <sup>9</sup> /L)	(10 <sup>9</sup> /L)	(10 <sup>9</sup> /L)	(10 <sup>9</sup> /L)	(10 <sup>9</sup> /L)
	-1	1	2	3	4	-1	1	2	3	4
RP6F01	1.0	1.3	2.2	.	.	53.9	67.6	118.9	.	.
RP6F02	1.1	1.7	1.5	3.1	2.6	64.3	97.2	84.8	163.3	145.9
RP6F03	0.4	0.3	0.6	4.5 E <sup>1</sup>	.	26.0	21.1	35.6	199.0 E <sup>1</sup>	.
RP6F04	0.8	1.2	1.2	2.4 E <sup>1</sup>	.	53.3	74.2	74.8	124.2 E <sup>1</sup>	.
Mean	0.8	1.1	1.4	3.1	2.6	49.4	65.0	78.5	163.3	145.9
S.D.	0.3	0.6	0.7	.	.	16.4	31.9	34.3	.	.
N	4	4	4	1	1	4	4	4	1	1

1 [E, Exclude]

TK13152

Page: 70

## A 4-Week Oral Dose Toxicity Study of TM5509 in Cynomolgus Monkeys

## Appendix 6 Hematology (females)

Sex: Female Week(s) Relative to Start Date

High TM5509 300 mg/kg/day	PLT	PLT	PLT	PLT	PLT	WBC	WBC	WBC	WBC	WBC
	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)
	-1	1	2	3	4	-1	1	2	3	4
RP6F01	448	463	595	.	.	5.66	5.93	7.34	.	.
RP6F02	344	359	418	400	382	10.11	6.24	6.78	8.20	7.15
RP6F03	563	643	905	764 E <sup>1</sup>	.	9.16	7.09	5.34	6.29 E <sup>1</sup>	.
RP6F04	418	392	696	597 E <sup>1</sup>	.	11.68	8.44	14.58	13.14 E <sup>1</sup>	.
Mean	443	464	654	400	382	9.15	6.93	8.51	8.20	7.15
S.D.	91	127	203	.	.	2.55	1.12	4.13	.	.
N	4	4	4	1	1	4	4	4	1	1

1 [E, Exclude]

## A 4-Week Oral Dose Toxicity Study of TM5509 in Cynomolgus Monkeys

## Appendix 6 Hematology (females)

Sex: Female Week(s) Relative to Start Date

High TM5509 300 mg/kg/day	%Neut	%Neut	%Neut	%Neut	%Neut	%Lymph	%Lymph	%Lymph	%Lymph	%Lymph
	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
	-1	1	2	3	4	-1	1	2	3	4
RP6F01	42.2	41.9	42.9	.	.	52.3	49.3	49.9	.	.
RP6F02	52.4	42.4	42.6	48.4	34.4	43.6	51.1	49.4	46.7	60.1
RP6F03	32.3	38.9	21.7	68.5 E <sup>1</sup>	.	61.1	51.8	68.7	28.0 E <sup>1</sup>	.
RP6F04	67.6	62.5	72.3	60.2 E <sup>1</sup>	.	29.2	31.9	24.1	33.4 E <sup>1</sup>	.
Mean	48.6	46.4	44.9	48.4	34.4	46.6	46.0	48.0	46.7	60.1
S.D.	15.1	10.8	20.8	.	.	13.6	9.5	18.3	.	.
N	4	4	4	1	1	4	4	4	1	1

1 [E, Exclude]



TK13152

Page: 72

## A 4-Week Oral Dose Toxicity Study of TM5509 in Cynomolgus Monkeys

## Appendix 6 Hematology (females)

Sex: Female Week(s) Relative to Start Date

High TM5509 300 mg/kg/day	%Mono					%Eos				
	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
	-1	1	2	3	4	-1	1	2	3	4
RP6F01	4.3	6.9	5.9	.	.	0.5	0.6	0.5	.	.
RP6F02	3.2	5.8	5.5	3.5	3.9	0.1	0.2	0.6	0.4	0.7
RP6F03	3.9	7.8	8.0	2.9 E <sup>1</sup>	.	1.7	0.5	0.8	0.1 E <sup>1</sup>	.
RP6F04	2.3	4.6	3.0	5.1 E <sup>1</sup>	.	0.4	0.4	0.1	0.3 E <sup>1</sup>	.
Mean	3.4	6.3	5.6	3.5	3.9	0.7	0.4	0.5	0.4	0.7
S.D.	0.9	1.4	2.1	.	.	0.7	0.2	0.3	.	.
N	4	4	4	1	1	4	4	4	1	1

1 [E, Exclude]

## A 4-Week Oral Dose Toxicity Study of TM5509 in Cynomolgus Monkeys

## Appendix 6 Hematology (females)

Sex: Female Week(s) Relative to Start Date

High TM5509 300 mg/kg/day	%Baso					%LUC				
	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)	(%)
	-1	1	2	3	4	-1	1	2	3	4
RP6F01	0.4	0.3	0.4	.	.	0.4	0.9	0.4	.	.
RP6F02	0.3	0.1	0.5	0.3	0.3	0.3	0.3	1.5	0.7	0.7
RP6F03	0.5	0.3	0.2	0.2 E <sup>1</sup>	.	0.5	0.7	0.6	0.2 E <sup>1</sup>	.
RP6F04	0.2	0.2	0.3	0.3 E <sup>1</sup>	.	0.2	0.4	0.2	0.8 E <sup>1</sup>	.
Mean	0.4	0.2	0.4	0.3	0.3	0.4	0.6	0.7	0.7	0.7
S.D.	0.1	0.1	0.1	.	.	0.1	0.3	0.6	.	.
N	4	4	4	1	1	4	4	4	1	1

1 [E, Exclude]

TK13152

Page: 74

## A 4-Week Oral Dose Toxicity Study of TM5509 in Cynomolgus Monkeys

## Appendix 6 Hematology (females)

Sex: Female Week(s) Relative to Start Date

High TM5509 300 mg/kg/day	#Neut	#Neut	#Neut	#Neut	#Neut	#Lymph	#Lymph	#Lymph	#Lymph	#Lymph
	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)
	-1	1	2	3	4	-1	1	2	3	4
RP6F01	2.39	2.49	3.15	.	.	2.96	2.93	3.66	.	.
RP6F02	5.30	2.65	2.89	3.97	2.46	4.41	3.19	3.35	3.83	4.30
RP6F03	2.96	2.76	1.16	4.31 E <sup>1</sup>	.	5.59	3.67	3.67	1.76 E <sup>1</sup>	.
RP6F04	7.90	5.27	10.54	7.90 E <sup>1</sup>	.	3.41	2.70	3.51	4.39 E <sup>1</sup>	.
Mean	4.64	3.29	4.44	3.97	2.46	4.09	3.12	3.55	3.83	4.30
S.D.	2.51	1.32	4.16	.	.	1.17	0.42	0.15	.	.
N	4	4	4	1	1	4	4	4	1	1

1 [E, Exclude]

## A 4-Week Oral Dose Toxicity Study of TM5509 in Cynomolgus Monkeys

## Appendix 6 Hematology (females)

Sex: Female Week(s) Relative to Start Date

High TM5509 300 mg/kg/day	#Mono	#Mono	#Mono	#Mono	#Mono	#Eos	#Eos	#Eos	#Eos	#Eos
	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)
	-1	1	2	3	4	-1	1	2	3	4
RP6F01	0.24	0.41	0.44	.	.	0.03	0.03	0.04	.	.
RP6F02	0.33	0.36	0.37	0.29	0.28	0.01	0.01	0.04	0.03	0.05
RP6F03	0.36	0.56	0.43	0.18 E <sup>1</sup>	.	0.16	0.04	0.04	0.01 E <sup>1</sup>	.
RP6F04	0.27	0.39	0.43	0.67 E <sup>1</sup>	.	0.05	0.03	0.02	0.04 E <sup>1</sup>	.
Mean	0.30	0.43	0.42	0.29	0.28	0.06	0.03	0.04	0.03	0.05
S.D.	0.05	0.09	0.03	.	.	0.07	0.01	0.01	.	.
N	4	4	4	1	1	4	4	4	1	1

1 [E, Exclude]

TK13152

Page: 76

## A 4-Week Oral Dose Toxicity Study of TM5509 in Cynomolgus Monkeys

## Appendix 6 Hematology (females)

Sex: Female Week(s) Relative to Start Date

High TM5509 300 mg/kg/day	#Baso	#Baso	#Baso	#Baso	#Baso	#LUC	#LUC	#LUC	#LUC	#LUC
	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)	(10 <sup>3</sup> /μL)
	-1	1	2	3	4	-1	1	2	3	4
RP6F01	0.02	0.02	0.03	.	.	0.02	0.05	0.03	.	.
RP6F02	0.03	0.01	0.03	0.03	0.02	0.03	0.02	0.10	0.06	0.05
RP6F03	0.04	0.02	0.01	0.01 E <sup>1</sup>	.	0.05	0.05	0.03	0.02 E <sup>1</sup>	.
RP6F04	0.03	0.02	0.04	0.04 E <sup>1</sup>	.	0.02	0.03	0.03	0.11 E <sup>1</sup>	.
Mean	0.03	0.02	0.03	0.03	0.02	0.03	0.04	0.05	0.06	0.05
S.D.	0.01	0.00	0.01	.	.	0.01	0.02	0.04	.	.
N	4	4	4	1	1	4	4	4	1	1

1 [E, Exclude]

## A 4-Week Oral Dose Toxicity Study of TM5509 in Cynomolgus Monkeys

## Appendix 6 Hematology (females)

Sex: Female Week(s) Relative to Start Date

High TM5509 300 mg/kg/day	PT	PT	PT	PT	PT	APTT	APTT	APTT	APTT	APTT
	(s)	(s)	(s)	(s)	(s)	(s)	(s)	(s)	(s)	(s)
	-1	1	2	3	4	-1	1	2	3	4
RP6F01	10.1	17.5	14.4	. <sup>1</sup>	.	24.1	35.4	30.5	64.4 <sup>E2</sup>	.
RP6F02	9.9	36.4	19.5	18.5	20.0	24.1	37.9	34.6	32.4	34.3
RP6F03	9.4	10.9	14.1	26.5 <sup>E2</sup>	.	22.8	26.1	32.1	37.9 <sup>E2</sup>	.
RP6F04	10.3	13.0	21.0	16.9 <sup>E2</sup>	.	24.7	29.2	36.4	34.9 <sup>E2</sup>	.
Mean	9.9	19.5	17.3	18.5	20.0	23.9	32.2	33.4	32.4	34.3
S.D.	0.4	11.6	3.5	.	.	0.8	5.4	2.6	.	.
N	4	4	4	1	1	4	4	4	1	1

1 [RC:Data not available since the blood did not coagulate.]

2 [E, Exclude]

## A 4-Week Oral Dose Toxicity Study of TM5509 in Cynomolgus Monkeys

## Appendix 6 Hematology (females)

Sex: Female Week(s) Relative to Start Date

High TM5509 300 mg/kg/day	Fib	Fib	Fib	Fib	Fib
	(mg/dL)	(mg/dL)	(mg/dL)	(mg/dL)	(mg/dL)
	-1	1	2	3	4
RP6F01	157.5	204.5	175.6	148.0 E <sup>1</sup>	.
RP6F02	190.0	233.3	162.6	236.1	230.4
RP6F03	152.5	213.3	192.6	194.5 E <sup>1</sup>	.
RP6F04	151.3	276.9	230.6	360.7 E <sup>1</sup>	.
Mean	162.8	232.0	190.4	236.1	230.4
S.D.	18.3	32.3	29.5	.	.
N	4	4	4	1	1

1 [E, Exclude]

## A 4-Week Oral Dose Toxicity Study of TM5509 in Cynomolgus Monkeys

## Appendix 7 Clinical chemistry (males)

Sex: Male Week(s) Relative to Start Date

Control 0.5%CMC-Na	AST (U/L)					ALT (U/L)				
	AST (U/L)	AST (U/L)	AST (U/L)	AST (U/L)	AST (U/L)	ALT (U/L)	ALT (U/L)	ALT (U/L)	ALT (U/L)	ALT (U/L)
	-1	1	2	3	4	-1	1	2	3	4
RP1M01	23	34	23	27	22	32	85	75	54	38
RP1M02	33	26	29	28	28	35	30	26	28	30
RP1M03	30	36	27	28	28	30	41	28	28	25
RP1M04	27	29	27	28	34	22	22	23	25	23
Mean	28	31	27	28	28	30	45	38	34	29
S.D.	4	5	3	1	5	6	28	25	14	7
N	4	4	4	4	4	4	4	4	4	4



TK13152

Page: 2

A 4-Week Oral Dose Toxicity Study of TM5509 in Cynomolgus Monkeys

Appendix 7 Clinical chemistry (males)

Sex: Male Week(s) Relative to Start Date

Control 0.5%CMC-Na	ALP (U/L)					LD (U/L)				
	ALP (U/L)	ALP (U/L)	ALP (U/L)	ALP (U/L)	ALP (U/L)	LD (U/L)	LD (U/L)	LD (U/L)	LD (U/L)	LD (U/L)
	-1	1	2	3	4	-1	1	2	3	4
RP1M01	1294	1128	1327	1120	1065	220	231	226	236	218
RP1M02	1050	1179	1321	1262	1284	337	326	309	325	308
RP1M03	1211	1504	1508	1399	1340	355	502	361	398	339
RP1M04	1900	2156	2418	1973	2033	279	366	249	298	307
Mean	1364	1492	1644	1439	1431	298	356	286	314	293
S.D.	372	473	524	374	419	61	112	61	67	52
N	4	4	4	4	4	4	4	4	4	4

## A 4-Week Oral Dose Toxicity Study of TM5509 in Cynomolgus Monkeys

## Appendix 7 Clinical chemistry (males)

Sex: Male Week(s) Relative to Start Date

Control 0.5%CMC-Na	CK (U/L)					GGT (U/L)				
	CK (U/L)	CK (U/L)	CK (U/L)	CK (U/L)	CK (U/L)	GGT (U/L)	GGT (U/L)	GGT (U/L)	GGT (U/L)	GGT (U/L)
	-1	1	2	3	4	-1	1	2	3	4
RP1M01	110	85	115	127	118	47.0	48.3	41.8	43.5	42.6
RP1M02	116	93	163	121	126	45.8	45.0	40.9	44.4	43.9
RP1M03	155	140	120	119	102	37.7	36.7	34.9	35.1	34.3
RP1M04	212	159	249	217	273	44.3	43.3	42.0	44.0	44.8
Mean	148	119	162	146	155	43.7	43.3	39.9	41.8	41.4
S.D.	47	36	62	47	79	4.1	4.9	3.4	4.4	4.8
N	4	4	4	4	4	4	4	4	4	4

TK13152

Page: 4

## A 4-Week Oral Dose Toxicity Study of TM5509 in Cynomolgus Monkeys

## Appendix 7 Clinical chemistry (males)

Sex: Male Week(s) Relative to Start Date

Control 0.5%CMC-Na	GLDH (U/L)					LAP (U/L)				
	GLDH (U/L)	GLDH (U/L)	GLDH (U/L)	GLDH (U/L)	GLDH (U/L)	LAP (U/L)	LAP (U/L)	LAP (U/L)	LAP (U/L)	LAP (U/L)
	-1	1	2	3	4	-1	1	2	3	4
RP1M01	13	67	26	21	16	50	46	50	56	55
RP1M02	12	11	10	12	10	37	35	31	35	35
RP1M03	8	12	8	9	8	65	61	58	58	55
RP1M04	8	11	10	10	9	36	33	34	33	35
Mean	10	25	14	13	11	47	44	43	46	45
S.D.	3	28	8	5	4	14	13	13	13	12
N	4	4	4	4	4	4	4	4	4	4

## A 4-Week Oral Dose Toxicity Study of TM5509 in Cynomolgus Monkeys

## Appendix 7 Clinical chemistry (males)

Sex: Male Week(s) Relative to Start Date

Control 0.5%CMC-Na	GLU (mg/dL)					BIL (mg/dL)				
	GLU (mg/dL)	GLU (mg/dL)	GLU (mg/dL)	GLU (mg/dL)	GLU (mg/dL)	BIL (mg/dL)	BIL (mg/dL)	BIL (mg/dL)	BIL (mg/dL)	BIL (mg/dL)
	-1	1	2	3	4	-1	1	2	3	4
RP1M01	53	72	77	86	70	0.27	0.14	0.11	0.07	0.08
RP1M02	88	78	95	91	96	0.12	0.12	0.10	0.07	0.08
RP1M03	96	75	96	84	101	0.12	0.17	0.12	0.08	0.08
RP1M04	84	84	89	99	90	0.13	0.16	0.11	0.10	0.12
Mean	80	77	89	90	89	0.16	0.15	0.11	0.08	0.09
S.D.	19	5	9	7	14	0.07	0.02	0.01	0.01	0.02
N	4	4	4	4	4	4	4	4	4	4